ALLMedicine™ Acute Myeloid Leukemia Center
Research & Reviews 24,159 results
https://doi.org/10.1158/1078-0432.CCR-20-3679
Clinical Cancer Research : an Official Journal of the Ame... Makela E, Pavic K et. al.
Mar 6th, 2021 - Cancerous inhibitor of PP2A (CIP2A) is an oncoprotein that inhibits the tumor suppressor PP2A-B56a. However, CIP2A mRNA variants remain uncharacterized. Here, we report the discovery of a CIP2Asplicing variant, NOCIVA (NOvel CIp2a VAriant). Charac...
https://doi.org/10.1038/s41409-021-01248-3 10.1056/NEJMsa1311707 10.1038/s41409-019-0610-5 10.1182/blood-2008-02-140095 10.1016/j.bbmt.2008.03.005 10.1002/cncr.31228 10.1038/leu.2015.75 10.1182/blood-2009-11-254441 10.1038/bmt.2015.305 10.1182/blood.V92.10.3515 10.1016/j.bbmt.2008.11.025 10.1016/j.bbmt.2014.06.011 10.1182/hematology.2019000056 10.1038/s41409-019-0499-z 10.1056/NEJMoa1203517 10.18632/oncotarget.8463 10.1182/blood.V89.12.4531 10.1016/j.bbmt.2020.06.026 10.1186/s13045-015-0182-9. 10.1016/j.bbmt.2010.02.013 10.1038/bmt.2014.250 10.1016/j.bbmt.2019.05.013
Bone Marrow Transplantation; Ruggeri A, Labopin M et. al.
Mar 6th, 2021 - The use of haplo-HCT with posttransplant cyclophosphamide (PT-Cy) is a new standard in the treatment of hematological diseases. A paucity of data exists on risk factors for engraftment failure in haplo-HCT with PT-Cy. We analyzed 1939 adults with ...
https://doi.org/10.1097/FPC.0000000000000431
Pharmacogenetics and Genomics; Megías-Vericat JE, Martínez-Cuadrón D et. al.
Mar 6th, 2021 - Genetic variability in anthracycline metabolism could modify the response and safety of acute myeloid leukemia (AML) induction. Polymorphisms in genes that encodes enzymes of anthracyclines metabolic pathway (CBR3: rs1056892, rs8133052, NQO1: rs18...
https://doi.org/10.1038/s41589-021-00742-5 10.1056/NEJMra1406184 10.1182/blood.V124.21.437.437 10.1182/blood-2009-05-222034 10.1182/blood-2013-07-513044 10.1182/blood-2019-124034 10.1182/blood.V128.22.102.102 10.1002/ajh.23308 10.1517/13543784.17.11.1623 10.1073/pnas.122233699 10.1007/s10147-007-0694-6 10.1038/sj.leu.2402807 10.1182/blood-2017-10-813139 10.1016/j.cub.2003.09.024 10.1158/0008-5472.CAN-17-1240 10.1021/acs.jmedchem.8b01469 10.1038/sj.emboj.7601675 10.1016/j.pharmthera.2017.02.027 10.1038/s41392-019-0101-6 10.1016/j.ccell.2019.10.002 10.1021/cb200519y 10.1038/nchembio.2538 10.1021/acs.jmedchem.9b00871 10.1016/j.bmcl.2019.03.035 10.1016/j.chembiol.2018.11.006 10.1002/anie.201901336 10.1016/j.ejmech.2019.111952 10.1021/jm050267e 10.1158/0008-5472.CAN-05-0882 10.1016/j.bmcl.2006.04.071 10.1038/nrc.2017.103 10.1016/j.ddtec.2019.01.002 10.1038/nchembio.2329 10.1038/s41589-018-0055-y 10.1016/j.chembiol.2017.09.010 10.4161/cc.4.8.1918 10.4049/jimmunol.1202313 10.1038/srep21664 10.1002/eji.200425154 10.1084/jem.20172246 10.1073/pnas.1905221116 10.1006/excr.2001.5200 10.1158/0008-5472.CAN-09-1947 10.1371/journal.pone.0168387 10.1038/s41467-019-09234-6 10.1093/nar/gky869 10.1016/j.gpb.2017.01.001 10.1093/nar/gkz1210
Nature Chemical Biology; Wang L, Shao X et. al.
Mar 5th, 2021 - The discovery of effective therapeutic treatments for cancer via cell differentiation instead of antiproliferation remains a great challenge. Cyclin-dependent kinase 2 (CDK2) inactivation, which overcomes the differentiation arrest of acute myeloi...
https://doi.org/10.1097/MD.0000000000024614
Medicine Huang YM, Wang YN et. al.
Mar 5th, 2021 - To investigate the prognostic value of the circulating peripheral blood cell counts changes in acute myeloid leukemia (AML) at different time points during induction chemotherapy.We retrospectively analyzed the clinical and laboratory data of 237 ...
Guidelines 95 results
https://doi.org/10.1016/j.bbmt.2020.09.020
Biology of Blood and Marrow Transplantation : Journal of ... Dholaria B, Savani BN et. al.
Sep 23rd, 2020 - The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence-based review. An AML expert panel, consisting of both transplant and...
https://ascopost.com/news/june-2020/ivosidenib-plus-venetoclax-with-or-without-azacitidine-for-idh1-mutated-aml/
May 31st, 2020 - Combination therapy with the isocitrate dehydrogenase 1 (IDH1) inhibitor ivosenidib plus the BCL2 inhibitor venetoclax with or without the chemotherapeutic agent azacitidine showed activity in patients with IDH1-mutated acute myeloid leukemia (AML...
https://www.onclive.com/conference-coverage/asco-2020/amg-330-shows-promise-in-treating-relapsedrefractory-aml
May 29th, 2020 - Findings showed that AMG 330 was safe and tolerable in treating patients with relapsed or refractory acute myeloid leukemia (AML), with cytokine release syndrome (CRS) as the most frequent and expected adverse event (AE), according to preliminary ...
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200172/full/
May 28th, 2020 - When patients with acute myeloid leukemia (AML) undergo intensive chemotherapy treatment, their quality of life (QoL) and mood are negatively affected. Areej El-Jawahri, MD, of Massachusetts General Hospital, presented the results of a multicenter...
https://www.jcancer.org/v10p6088.htm
Journal of Cancer; Hu N,et al
Oct 14th, 2019 - DOCK family proteins are evolutionarily conserved guanine nucleotide exchange factors for Rho GTPase with different cellular functions. It has been demonstrated that DOCK1 had adverse prognostic effect in acute myeloid leukemia (AML).
Drugs 59 results see all →
Clinicaltrials.gov 25,251 results
https://doi.org/10.1158/1078-0432.CCR-20-3679
Clinical Cancer Research : an Official Journal of the Ame... Makela E, Pavic K et. al.
Mar 6th, 2021 - Cancerous inhibitor of PP2A (CIP2A) is an oncoprotein that inhibits the tumor suppressor PP2A-B56a. However, CIP2A mRNA variants remain uncharacterized. Here, we report the discovery of a CIP2Asplicing variant, NOCIVA (NOvel CIp2a VAriant). Charac...
https://doi.org/10.1038/s41409-021-01248-3 10.1056/NEJMsa1311707 10.1038/s41409-019-0610-5 10.1182/blood-2008-02-140095 10.1016/j.bbmt.2008.03.005 10.1002/cncr.31228 10.1038/leu.2015.75 10.1182/blood-2009-11-254441 10.1038/bmt.2015.305 10.1182/blood.V92.10.3515 10.1016/j.bbmt.2008.11.025 10.1016/j.bbmt.2014.06.011 10.1182/hematology.2019000056 10.1038/s41409-019-0499-z 10.1056/NEJMoa1203517 10.18632/oncotarget.8463 10.1182/blood.V89.12.4531 10.1016/j.bbmt.2020.06.026 10.1186/s13045-015-0182-9. 10.1016/j.bbmt.2010.02.013 10.1038/bmt.2014.250 10.1016/j.bbmt.2019.05.013
Bone Marrow Transplantation; Ruggeri A, Labopin M et. al.
Mar 6th, 2021 - The use of haplo-HCT with posttransplant cyclophosphamide (PT-Cy) is a new standard in the treatment of hematological diseases. A paucity of data exists on risk factors for engraftment failure in haplo-HCT with PT-Cy. We analyzed 1939 adults with ...
https://doi.org/10.1097/FPC.0000000000000431
Pharmacogenetics and Genomics; Megías-Vericat JE, Martínez-Cuadrón D et. al.
Mar 6th, 2021 - Genetic variability in anthracycline metabolism could modify the response and safety of acute myeloid leukemia (AML) induction. Polymorphisms in genes that encodes enzymes of anthracyclines metabolic pathway (CBR3: rs1056892, rs8133052, NQO1: rs18...
https://doi.org/10.1038/s41589-021-00742-5 10.1056/NEJMra1406184 10.1182/blood.V124.21.437.437 10.1182/blood-2009-05-222034 10.1182/blood-2013-07-513044 10.1182/blood-2019-124034 10.1182/blood.V128.22.102.102 10.1002/ajh.23308 10.1517/13543784.17.11.1623 10.1073/pnas.122233699 10.1007/s10147-007-0694-6 10.1038/sj.leu.2402807 10.1182/blood-2017-10-813139 10.1016/j.cub.2003.09.024 10.1158/0008-5472.CAN-17-1240 10.1021/acs.jmedchem.8b01469 10.1038/sj.emboj.7601675 10.1016/j.pharmthera.2017.02.027 10.1038/s41392-019-0101-6 10.1016/j.ccell.2019.10.002 10.1021/cb200519y 10.1038/nchembio.2538 10.1021/acs.jmedchem.9b00871 10.1016/j.bmcl.2019.03.035 10.1016/j.chembiol.2018.11.006 10.1002/anie.201901336 10.1016/j.ejmech.2019.111952 10.1021/jm050267e 10.1158/0008-5472.CAN-05-0882 10.1016/j.bmcl.2006.04.071 10.1038/nrc.2017.103 10.1016/j.ddtec.2019.01.002 10.1038/nchembio.2329 10.1038/s41589-018-0055-y 10.1016/j.chembiol.2017.09.010 10.4161/cc.4.8.1918 10.4049/jimmunol.1202313 10.1038/srep21664 10.1002/eji.200425154 10.1084/jem.20172246 10.1073/pnas.1905221116 10.1006/excr.2001.5200 10.1158/0008-5472.CAN-09-1947 10.1371/journal.pone.0168387 10.1038/s41467-019-09234-6 10.1093/nar/gky869 10.1016/j.gpb.2017.01.001 10.1093/nar/gkz1210
Nature Chemical Biology; Wang L, Shao X et. al.
Mar 5th, 2021 - The discovery of effective therapeutic treatments for cancer via cell differentiation instead of antiproliferation remains a great challenge. Cyclin-dependent kinase 2 (CDK2) inactivation, which overcomes the differentiation arrest of acute myeloi...
https://doi.org/10.1097/MD.0000000000024614
Medicine Huang YM, Wang YN et. al.
Mar 5th, 2021 - To investigate the prognostic value of the circulating peripheral blood cell counts changes in acute myeloid leukemia (AML) at different time points during induction chemotherapy.We retrospectively analyzed the clinical and laboratory data of 237 ...
News 1,493 results
https://www.medscape.com/viewarticle/946434
Feb 23rd, 2021 - Updated February 25, 2021 // Editor’s note: The original text has been corrected to accurately reflect the status of the patients with AML and MDS. The FDA placed a clinical hold yesterday on two gene therapy trials for sickle cell disease (SCD) a...
https://reference.medscape.com/viewarticle/943967
Jan 27th, 2021 - Myelodysplastic syndrome (MDS) is a group of related hematopoietic disorders characterized by peripheral blood cytopenias, abnormal blood cell development, and clonal genetic markers. Patients with MDS may present with clinical manifestations of a...
https://www.medscape.com/viewarticle/943743
Jan 6th, 2021 - A new adverse event has been reported for PARP inhibitor drugs used in the treatment of cancer: the risk of developing myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), both of which have a high mortality rate. PARP inhibitors are...
https://www.medscape.com/viewarticle/942309
Dec 8th, 2020 - Black race is the most important risk factor for patients with acute myeloid leukemia (AML) and is associated with poor survival, according to new findings. Among patients with AML younger than 60 years, the rate of overall 3-year survival was sig...
https://www.medscape.com/viewarticle/940843
Nov 11th, 2020 - Precision medicine therapy proved feasible and superior to standard-of-care (SOC) chemotherapy in patients with acute myeloid leukemia in the Beat AML Master Clinical Trial. The 30-day mortality rates were 3.7% versus 20.4% in 224 patients who enr...
